Addressing serious unmet medical needs in cardiac care through continuous point-of-care biomarker surveillance — engineered to detect what traditional monitoring cannot, before it becomes an event.
The troponin assay transformed how clinicians detect myocardial injury. But the way we measure it hasn't changed. Alycium is building the platform to change that.
Real-time cardiac biomarker monitoring that moves beyond periodic sampling to deliver uninterrupted biochemical insight.
Designed to identify subclinical cardiac injury in real time, narrowing the critical gap between onset and clinical recognition.
Engineered for deployment at the point of care — bringing laboratory-grade biomarker analysis directly to the patient.
All product candidates are investigational and have not been cleared or approved by the U.S. Food and Drug Administration. There is no guarantee that any product candidate will receive regulatory clearance or approval, or that it will be commercially successful.
Our pipeline spans multiple cardiac diagnostic modalities, each addressing a distinct unmet clinical need.
Explore Pipeline →